Your browser doesn't support javascript.
loading
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice
Alexandra C Walls; Laura A VanBlargan; Kai Wu; Angela Choi; Mary Jane Navarro; Diana Lee; Laura Avena; Daniela Montes Berrueta; Minh N. Pham; Sayda Elbashir; Marcos C. Miranda; Elizabeth Kepl; Max Johnson; Alyssa Blackstone; Kaitlin R. Sprouse; Brooke Fiala; Natalie Brunette; Prabhu S Arunachalam; Lisa Shirreff; Kenneth A. Rogers; Lauren Carter; Deborah Heydenburg Fuller; Francois J Villinger; Bali Pulendran; Michael S Diamond; Darin K Edwards; Neil P King; David Veesler.
Afiliação
  • Alexandra C Walls; University of Washington
  • Laura A VanBlargan; Washington University
  • Kai Wu; Moderna, Inc.
  • Angela Choi; Moderna Inc.
  • Mary Jane Navarro; University of Washington
  • Diana Lee; Moderna, Inc.
  • Laura Avena; Moderna, Inc.
  • Daniela Montes Berrueta; Moderna, Inc.
  • Minh N. Pham; University of Washington
  • Sayda Elbashir; Moderna, Inc.
  • Marcos C. Miranda; University of Washington
  • Elizabeth Kepl; University of Washington
  • Max Johnson; University of Washington
  • Alyssa Blackstone; University of Washington
  • Kaitlin R. Sprouse; University of Washington
  • Brooke Fiala; University of Washington
  • Natalie Brunette; University of Washington
  • Prabhu S Arunachalam; Stanford University
  • Lisa Shirreff; University of Louisiana
  • Kenneth A. Rogers; University of Louisiana at Lafayette
  • Lauren Carter; University of Washington
  • Deborah Heydenburg Fuller; University of Washington
  • Francois J Villinger; University of Louisiana at Lafayette
  • Bali Pulendran; Stanford University
  • Michael S Diamond; Washington University School of Medicine
  • Darin K Edwards; Moderna Inc
  • Neil P King; University of Washington
  • David Veesler; University of Washington
Preprint em En | PREPRINT-BIORXIV | ID: ppbiorxiv-479468
ABSTRACT
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has led to the development of a large number of vaccines, several of which are now approved for use in humans. Understanding vaccine-elicited antibody responses against emerging SARS-CoV-2 variants of concern (VOC) in real time is key to inform public health policies. Serum neutralizing antibody titers are the current best correlate of protection from SARS-CoV-2 challenge in non-human primates and a key metric to understand immune evasion of VOC. We report that vaccinated BALB/c mice do not recapitulate faithfully the breadth and potency of neutralizing antibody responses against VOC, as compared to non-human primates or humans, suggesting caution should be exercised when interpreting data for this animal model.
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
...